Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. (ARCT) is a clinical-stage RNA medicines company pioneering novel therapeutics and vaccines through its proprietary delivery platforms. This news hub provides investors and researchers with timely updates on the company's progress in developing self-amplifying mRNA (sa-mRNA) vaccines and rare disease treatments.
Access official press releases covering regulatory milestones, clinical trial developments, and strategic partnerships. Our curated collection includes updates on the LUNAR® delivery system's applications, STARR® mRNA technology advancements, and global collaborations like the ARCALIS joint venture in Japan.
Key updates include earnings reports, research publications, manufacturing expansions, and patent grants. Bookmark this page for direct access to primary source materials about ARCT's work in nucleic acid therapeutics, including programs targeting liver disorders, respiratory diseases, and infectious disease prevention.
For stakeholders tracking RNA medicine innovation, this repository offers organized chronological updates without promotional commentary. Check regularly for verified information about clinical-stage candidates and technology licensing agreements that demonstrate Arcturus' position in the biotechnology sector.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced it will release its financial results for the quarter ended March 31, 2023, after the market close on May 9, 2023. The Company, focused on mRNA medicines for infectious disease vaccines and rare diseases, will also host a conference call and webcast at 4:30 PM ET on the same day. Established in 2013 and based in San Diego, Arcturus utilizes innovative delivery technologies like LUNAR® and STARR™ mRNA Technology. Its pipeline includes candidates for treating ornithine transcarbamylase deficiency and cystic fibrosis, alongside partners in mRNA vaccine programs for COVID-19 and influenza. For more details, visit www.ArcturusRx.com.
Arcturus Therapeutics Holdings announced significant financial results for Q4 2022, highlighting a revenue surge to $160.3 million, driven by a $200 million payment from CSL collaboration. The company achieved $90 million in development milestones in March 2023, bolstering its cash runway into 2026. ARCT-154 Phase 3 trial for COVID-19 booster is fully enrolled in Japan, with ARCT-810 and ARCT-032 advancing in clinical trials. The company reported a net income of $117.3 million for Q4, compared to a loss the previous year. Cash balance was $391.9 million at year-end, reflecting a robust financial position.
FAQ
What is the current stock price of Arcturus Therape (ARCT)?
What is the market cap of Arcturus Therape (ARCT)?
